brendanwarmack

brendanwarmack

NASDAQ:NKTX Looking like a technical reversal on the daily chart - MACD, TTM, and MACD look very resilient after a selloff. Analysts set price targets at 15$, indicators seem to match up with this. Earnings in 17 days and mid-year treatment trials could be catalysts to move the price towards this target. Earlier results were promising. Make sure to manage...

brendanwarmack

NASDAQ:LULU Lululemon Athletica's Q4 performance exceeded expectations, with revenues rising 16% and gross margins growing by 4.3%. However, increased competition and price-conscious consumers have led to a decreased market cap and short-term headwinds. Gross margins remain at 58% leading the industry and showing the prominence of the brand. Lululemon has had...

brendanwarmack

NASDAQ:NKTX is a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. While highly speculative, the daily charts have presented a purchasing opportunity after a stock offering to raise capital. MACD and TTM Squeeze tend to be reversing, and selling pressure seems to...

brendanwarmack

I've previously posted my article on the strength and potential of NYSE:ML as a company. My thesis still stands in a mid-term perspective. Additionally, lowering of interest rates and a rotation out of large cap stocks will be very beneficial for Moneylion. On a technical level, MACD, RSI, and TTM Squeeze prove strong on the 4H chart. Additionally, 9...

brendanwarmack

NYSE:ML Moneylion, a corporation with a highly effective marketing strategy through media and social media influencers, currently has nowhere to go but up. With a CAC (customer acquisition cost) of only 15$, growing EPS and EPS estimate, and a estimation of profitability by 2025 - Moneylion creates a great entry point following the recent pullback. Thesis:...